Can low-grade inflammation and a high AA/EPA ratio remodel HDL particles?

Standard lipid panels that measure total high-density lipoprotein cholesterol (HDL-C) often obscure critical structural and functional changes occurring at the molecular level. Emerging evidence highlights that qualitative remodeling of HDL particles can occur independently of total cholesterol levels, driven by systemic inflammation and fatty acid imbalances.

Mechanistic drivers of HDL remodeling

• Apolipoprotein displacement: Systemic low-grade inflammation induces an acute-phase response that enriches HDL particles with Serum Amyloid A (SAA), directly displacing its primary structural protein, apolipoprotein A-I (ApoA-I).
• Enzymatic restructuring: Chronic inflammatory states activate secretory phospholipase A2 (sPLA2) and cholesteryl ester transfer protein (CETP), which hydrolyze and restructure the HDL lipid core, destabilizing the particle.
• Polyunsaturated fatty acid influence: A high arachidonic acid (AA) to eicosapentaenoic acid (EPA) ratio acts as a key marker of pro-inflammatory tone, facilitating this remodeling. Conversely, EPA enrichment shifts the lipid pool to restore HDL's anti-oxidative and anti-inflammatory properties.

Subclass shift and functional impairment

• Loss of larger subclasses: This inflammatory and lipid-mediated remodeling shifts the particle distribution away from larger, buoyant, cardioprotective subclasses (such as HDL2b) toward smaller, denser, lipid-poor particles.
• Impaired cholesterol efflux: The accumulation of SAA and structural degradation directly impair HDL's cholesterol efflux capacity, particularly hindering ABCA1-mediated lipid clearance.
• Independence from HDL-C: These profound changes in size, subclass distribution, and anti-inflammatory capacity occur without necessarily altering total HDL-C concentrations, which can remain within acceptable clinical ranges.

Bottom line

• Low-grade inflammation and an elevated AA/EPA ratio cooperatively drive the remodeling of HDL into smaller, dysfunctional particles with impaired cholesterol efflux capacity, a process that remains completely hidden on standard HDL-C tests.